The latest from Dr. Falk Pharma
Welcome to our Newsroom, providing you with the latest news, press releases, clinical trial announcements, events, and more from Dr. Falk Pharma.
Follow us on LinkedIn!

Following the footsteps of our founder - The End
Elena looks back and summarizes her journey: it's a collection of emotional encounters, funny moments, and, most of all, it's a big THANK YOU!

Back to the Future – Unleashing the Power of Established Drugs
Lunch satellite symposium on 21.02.2025 during the Congress of ECCO in Berlin

Dr. Falk Pharma acquires Kynos Therapeutics
...adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio


Following the footsteps of our founder
Herbert Falk's granddaughter Elena decided to follow her grandpa's footsteps. Why? Find out more and follow Elena on her journey.

Dosing of the First United States Patient
...and expansion of the Phase 2b Study of Naronapride in Gastroparesis


New Addition to the Management Board
The new Technical Operations business unit will be headed up by Dr. Andreas Rascher

FDA clearance of IND application for naronapride
...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US

Advancing the development of naronapride...
...for patients with PPI-non-responsive symptomatic GERD as the second naronapride indication